STOCK TITAN
  1. Home
  2. News
  3. PVL
  4. Permianville Royalty Trust Announces Filing of Annual Report on Form 10-K

Permianville Royalty Trust Announces Filing of Annual Report on Form 10-K

Permianville Royalty Trust (NYSE: PVL) has announced the filing of its Annual Report on Form 10-K for the year ended December 31, 2024, with the SEC on March 19, 2025.

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment worksHow the balance works

Tags
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

HOUSTON--(BUSINESS WIRE)-- Permianville Royalty Trust (NYSE: PVL) (the “Trust”) today announced that its Annual Report on Form 10-K for the year ended December 31, 2024 was filed with the SEC on March 19, 2025. The Annual Report on Form 10-K is available in the “SEC Filings” section of the Trust’s website at www.permianvilleroyaltytrust.com, as well as on the SEC’s website at www.sec.gov. Trust unitholders have the ability to request a printed copy of the Annual Report on Form 10-K, which contains the Trust’s audited financial statements, free of charge (via first class mail) by sending a written request to Permianville Royalty Trust, The Bank of New York Mellon Trust Company, N.A., 601 Travis Street, 16th Floor, Houston, TX 77002.

Permianville Royalty Trust
The Bank of New York Mellon Trust Company, N.A., as Trustee
601 Travis Street, 16th Floor
Houston, Texas 77002
Sarah Newell 1 (512) 236-6555

Source: Permianville Royalty Trust

Keep reading

More on PVL

All PVL news

Trending in the feed

PCVX
Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate Open the live feed
View all latest news